ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia

Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-07, Vol.377 (3), p.296-297
Hauptverfasser:	Gaudet, Daniel, Gipe, Daniel A, Pordy, Robert, Ahmad, Zahid, Cuchel, Marina, Shah, Prediman K, Chyu, Kuang-Yuh, Sasiela, William J, Chan, Kuo-Chen, Brisson, Diane, Khoury, Etienne, Banerjee, Poulabi, Gusarova, Viktoria, Gromada, Jesper, Stahl, Neil, Yancopoulos, George D, Hovingh, G. Kees
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiopoietin-like Proteins Angiopoietins - antagonists & inhibitors Antibodies, Monoclonal - therapeutic use Cholesterol, LDL - blood Genotype Humans Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - drug therapy Hyperlipoproteinemia Type II - genetics Receptors, LDL - drug effects Receptors, LDL - genetics Receptors, LDL - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Evinacumab, a monoclonal antibody that blocks ANGPTL3, was administered to nine adults with homozygous familial hypercholesterolemia. At 4 weeks, LDL cholesterol was reduced by a mean of 49%, with a mean absolute change from baseline of −157 mg per deciliter.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc1705994